Welcome to
The Nordic Society of
Gynaecological Oncology
Gynaecological Oncology
Recruitment Status
Trial recruitment status - updated every month
Project manager overview
Contact the PM's of NSGO-CTU
Trial overview
Information & Design / Ongoing Trials
Members Application
For individuals in a Nordic country, who is professionally or scientifically active in the field of gynaecological cancer.
Publication overview
Contributions from members of NSGO.
NSGO-CTU Sites
An Overview Over Active Sites
NSGO-CTU Investigator Meeting
New PM – Karen Stampe
Welcome to our new Project Manager Karen Stampe Petersson has
INOVATYON/ ENGOT-ov5 Trial publication
Results from the MaNGO lead study INOVATYON/ ENGOT-ov5 The Novemeber
New NSGO-CTU collaboration with Kancera
We are very happy to announce that Kancera will collaborate
ENGOT Workshop in Malaga
ENGOT Workshop in Malaga The 2022 GCA edition is organized by
New PM – Bolette Buchner
Welcome to our new Project Manager Bolette Buchner Vinum has a
ENGOT-EN6/GOG-3031/NSGO-RUBY STUDY
Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study to Evaluate Dostarlimab Plus
AGO-OVAR 17 BOOST/GINECO
Results from AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 The Novemeber edition
ESGO 2022 – A great
ESGO 2022 / Berlin Thank you, European Society of Gynaecological Oncology Berlin
New PM – Stine Randeris
Welcome to our new Project Manager Welcome to our new
NSGO-CTU Office Themeday – Workshop
NSGO-CTU Theme day - Sep. 2022 Twice a year, the
ESMO 2022 – Line Bjørge: Some of the patients with ovarian cancer who received olaparib were cured. The SOLO-1 study shows that 67 percent of patients with advanced ovarian cancer with BRCA mutations who were treated with the PARP inhibitor Olaparib were alive after 7 years compared to 47 percent in the placebo group. – Some of the patients with ovarian cancer who received olaparib were cured. This is a big step forward for our patients.
Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses recent improvements in immune-oncology, specifically immune checkpoint inhibitors, for patients with endometrial or cervical cancer. There have been big developments in this field in recent years, with several therapies being approved in the EU and USA. Several Phase III trials are likely to produce interesting data in the near future. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague